
Please try another search
Reneuron Group (LON:RQE) continues to prepare for its Phase III chronic stroke study (due to start in H217) and has indicated that it is making progress with the US/EU regulatory authorities. It intends to submit an IND in the US in Q217 and shortly after in the EU. ReNeuron also announced that it now plans to expand its ongoing Phase I/II retinitis pigmentosa (hRP cells) study to 20 patients in Phase II and commence a Phase II study in a new indication: cone-rod dystrophy (CRD). As a result, it will not continue development of CTX in critical limb ischaemia (CLI). We maintain our rNPV at £291m.
Phase III chronic stroke study set-up progressing
ReNeuron reported positive Phase II trial data (December 2016) for its CTX cells in chronic stroke patients. It has recently announced that it is on track to initiate the follow-on Phase III trial in H217. It is currently consulting with the regulatory bodies in Europe and the US, has an end-of-Phase II meeting with the FDA shortly and intends to submit an IND in Q217. The European clinical trial application will follow shortly after. Alongside this, discussions are ongoing with the Japanese regulatory agency, which could offer a conditional marketing approval. For more detail, see our March 2017 outlook note.
To read the entire report Please click on the pdf File Below
Lately, we discussed macro-related market issues such as the A.I. chase, but a technical review can help manage shorter-term risks. Currently, the debate is about the market rally...
Intel and Nvidia are examples of two extremes One stock has gone parabolic, while the other one has been in a strong downtrend Let's take a closer look at both cases using...
Apple, Microsoft, Saudi Aramco, Alphabet, and Amazon are trillion-dollar companies In this piece, we will analyze the pros and cons of investing in these companies To help you make...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.